Sanofi-aventis’ diverse business model has helped compensate against generic competition in Q3.
SA generated net sales of €7.821m after seeing growth across its consumer, generic and vaccine divisions. However, a decline in sales is expected after the unexpected approval of a generic Lovenox product, and due to the loss of European patent exclusivity on Plavix.
The company remains in negotiation with Genzyme regarding an acquisition, although sanofi is not expected to increase its $69 per share offer.
AstraZenca has seen a sharp decline in US sales due to generic exposure in Q3.
Arimidex, Pulmicort Respules and Toprol-XL were the key casualties, and the loss of patent exclusivity on Symbicort, Seroquel and Nexium over the next few years could see revenue continue to fall.
Although sales of Crestor and Symbicort were up 20% and 19% respectively, the two will also be in competition with generics when released next year.
The company has not followed other pharma companies in diversifying into lower margins, and remains heavily tied to new product launches and the progression of late stage products to boost revenue.